Christopher Cunio's Contact Details

Christopher Cunio's Company Details

ORIG3N

Boston, MA, US • 20 - 49 Employees
BioTech/Drugs

Orig3n received Emergency Use Authorization clearance for their COVID-19 test on April 10, 2020. In addition to continuing work to provide the world with more knowledge about themselves based on their DNA, Orig3n is providing much needed COVID-19 capacity to nursing homes, boarding schools, clinicians, and underserved communities across the country.Orig3n helps people understand the links between their genes and how their minds and bodies work. From fitness to nutrition to personality, our DNA tests provide easy, affordable access to genetic information and guidance on how to use it. We help people take charge of their health with the knowledge they need to make more informed choices.Founded in 2014, Boston based Orig3n exists at the intersection of biological science and emerging technology. Through our DNA tests and community events, we help people understand the links between their genes and how their minds and bodies work. Our research team uses cutting-edge cellular science to develop personalized therapies for repairing tissue damage and disease. Together with our community, we're on a mission to accelerate the future of regenerative medicine. Find out more at orig3n.com.